Antibiotic combination therapies
Inventors
Trebosc, Vincent • Kemmer, Christian • Dale, Glenn E. • Lociuro, Sergio • Gitzinger, Marc
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11207305-B2
Publication Date
2021-12-28
Expiration Date
Abstract
The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.
Core Innovation
The invention relates to rifabutin-based antibiotic combination therapies for treating an A. baumannii infection in a subject. The approach provides rifabutin together with a second antibiotic selected from the group consisting of colistin and cefiderocol in a therapeutically effective amount.
The disclosed subject matter also addresses A. baumannii strains with resistance features, including strains that are resistant to rifabutin and strains comprising an rpoB mutation. The combination therapy is described as treating an A. baumannii infection in such contexts using rifabutin in combination with colistin or cefiderocol.
The disclosure reports unexpected in vitro synergy for rifabutin-based combinations with colistin and with cefiderocol across MDR/XDR A. baumannii strains. The synergy is described using checkerboard synergy evaluation and Fractional Inhibitory Concentration Index (FICI), including isolates resistant to one or both agents.
Claims Coverage
The partial claims identify two independent claims, covering both a method of treating an A. baumannii infection and a combination therapy formulation of rifabutin with a second antibiotic selected from colistin or cefiderocol. Across the independent claims, the key inventive elements center on the rifabutin + (colistin or cefiderocol) pairing and providing those components in therapeutically effective amounts to treat the infection.
Rifabutin with colistin or cefiderocol for treating an A. baumannii infection
A method of treating an A. baumannii infection in a subject by providing to a subject infected with A. baumannii rifabutin and a second antibiotic selected from the group consisting of colistin and cefiderocol.
Combination therapy of rifabutin with colistin or cefiderocol in a therapeutically effective amount
A combination therapy comprising rifabutin and a second antibiotic selected from the group consisting of colistin and cefiderocol, wherein the combination therapy comprises rifabutin and the second antibiotic in a therapeutically effective amount to treat an A. baumannii infection in a subject.
Both independent claims are directed to rifabutin-based therapy for A. baumannii infections using a second antibiotic selected from colistin or cefiderocol, with the combination provided in a therapeutically effective amount or as a treatment method.
Stated Advantages
Unexpected in vitro synergy for rifabutin-based combinations with colistin and with cefiderocol across MDR/XDR A. baumannii strains.
Synergy is described for isolates resistant to one or both agents.
Documented Applications
Treatment of an A. baumannii infection in a subject.
Interested in licensing this patent?